Impact of immunophenotype on prognosis of patients with myelodsyplastic syndromes. Its value in patients without karyotypic abnormalities

Hematology Journal

Volumn 5, Issue 3, 2004, Pages 227-233

  Arroyo, Jose L ^a   Fernández, Ma Eugenial ^a   Hernández, Jesús Maria ^a   Orfao, Alberto ^b   San Miguel, Jesús Fernando ^a   del Cañizo, Maria Consuelo ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Immunophenotype; Karyotype; Myelodysplastic; Prognosis; Syndromes

Indexed keywords

CD15 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW CELL; CELL COUNT; CELL CULTURE; CLONAL VARIATION; COLONY FORMING UNIT GM; COLOR; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; GENETIC DISORDER; GENETIC MARKER; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MITOSIS; MONOCYTE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; OUTCOMES RESEARCH; PHENOTYPE; PREDICTION; PROGNOSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL;

ANTIGENS, CD; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 3142769896     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200370     Document Type: Article

References (25)

1. Bennett JM, Catovsky D, Daniel MT, Fladrin G, Galton D, Granilck HR et al. The French-American-British Cooperative Group: proposals for the classification of the myelodysplastic syndromes. B J Haematol 1982; 51: 189-199.
2. Stetler-Stevenson N, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barret AJ et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979-987.
3. Mittelman M, Karcher DS, Kammerman LA, Lessin LS. High Ia (HLA-DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes. Am J Hematol 1993; 43: 165-171.
4. Ogata K, Nakamura N, Yokose N, Tamura H, Tachibana M, Taniguchi O et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 3887-3896.
5. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394-403.
6. Maynadie M, Picard F, Husson B, Chatelain B, Cornet Y, Le Roux G et al. Immunophenotypic clustering of myelodisplastic syndromes. Blood 2002; 100: 2349-2356.
7. Greenberg PL. Biological and clinical implications of marrow culture studies in the myelodysplastic syndromes. Semin Hematol 1996; 33: 163-175.
8. Verhoef GE, Pittaluga S, Wolf-Peeters C, Boogaerts MA. FAB classification of myelodysplastic syndromes: merits and controversies. Ann Hematol 1995; 71: 3-11.
9. Catalano L, Improta S, de Laurentiis M, Molica S, Majolino I, Musto P et al. Prognosis of chronic myelomonocytic leukemia. Haematologica 1996; 81: 324-329.
10. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840-849.
11. ISCN. In: F Mitelman (ed). An International System for Human Cytogenetic Nomenclature. S. Karger: Basel 1995.
12. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
13. Del Canizo MC, Fernandez ME, Lopez A, Vidriales B, Villaron E, Arroyo JL et al. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 2003; 88: 402-407.
14. Buick R, Till JE, McCulloch EA. Colony assay for proliferative blast progenitor cells circulating in myeloblastic leukaemia. Lancet 1977; i: 862-863.
15. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-483.
16. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187.
17. Boogaerts M, Verhoef GE, Demunynck H. Treatment and prognostic factors in myelodysplastic syndromes. Baillieres Clin Haematol 1996; 9: 161-183.
18. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 9: 425-433.
19. Sanz GF, Sanz MA, Vallespi T, del Cañizo MC, Torrabadella M, Garcia S et al. Two regression models and a scoring system for predicting survival and planing tratment in myelodysplastic Syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
20. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7: 1315-1323.
21. Sole F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luno E et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000; 108: 346-356.
22. Guyotat D, Campos L, Thomas X, Vila L, Shi ZH, Charrin C et al. Myelodysplastic syndromes: a study of surface markers and in vitro growth patterns. Am J Hematol 1993; 34: 26-31.
23. Kristensen JS, Hokland P. Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. Br J Haematol 1990; 74: 270-276.
24. Jensen IM, Hokland P. The proliferative activity of myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry. Br J Haematol 1994; 87: 477-482.
25. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470.